HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bio-One acquisition

This article was originally published in The Tan Sheet

Executive Summary

Orlando, Fla.-based supplement firm purchases fifth majority stake in a Chinese herbal company in recent months with acquisition of 51% share of a firm in the Henan Province; the acquisition is expected to close in 90 days. The Chinese firm, which reported $17 mil. in 2003 revenues, will retain its present management team. The deal continues Bio-One's vertical integration and international expansion strategy following the April purchase of Canadian distributor and manufacturer INI (1"The Tan Sheet" April 12, 2004, p. 12)...

You may also be interested in...



Bio-One Supplement Firm Buys Interactive Nutrition International

Bio-One continues its aggressive acquisition strategy with its purchase of Canadian manufacturer and distributor Interactive Nutrition International, the firm announced April 1

Abbott Readying Vildagliptin ER In India Amid Price Competition

Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.

AstraZeneca's Risky Lynparza Endpoint In Pancreatic Cancer Goes Before Advisory Cmte.

US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.

Topics

UsernamePublicRestriction

Register

RS128072

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel